These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 33784491)

  • 1. CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
    Tsoyi K; Liang X; De Rossi G; Ryter SW; Xiong K; Chu SG; Liu X; Ith B; Celada LJ; Romero F; Robertson MJ; Esposito AJ; Poli S; El-Chemaly S; Perrella MA; Shi Y; Whiteford J; Rosas IO
    Am J Respir Crit Care Med; 2021 Aug; 204(3):312-325. PubMed ID: 33784491
    [No Abstract]   [Full Text] [Related]  

  • 2. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
    Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
    PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eupatilin inhibits pulmonary fibrosis by activating Sestrin2/PI3K/Akt/mTOR dependent autophagy pathway.
    Gong H; Lyu X; Liu Y; Peng N; Tan S; Dong L; Zhang X
    Life Sci; 2023 Dec; 334():122218. PubMed ID: 37918625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis.
    Zhang L; Li Y; Liang C; Yang W
    Int J Mol Med; 2014 Feb; 33(2):478-86. PubMed ID: 24276150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 21 alleviates idiopathic pulmonary fibrosis by inhibiting PI3K-AKT-mTOR signaling and stimulating autophagy.
    Qi J; Wu Y; Guo Z; Zhu S; Xiong J; Hu F; Liang X; Ye X
    Int J Biol Macromol; 2024 Jul; 273(Pt 1):132896. PubMed ID: 38851619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148.
    Tsoyi K; Chu SG; Patino-Jaramillo NG; Wilder J; Villalba J; Doyle-Eisele M; McDonald J; Liu X; El-Chemaly S; Perrella MA; Rosas IO
    Am J Respir Cell Mol Biol; 2018 Feb; 58(2):208-215. PubMed ID: 28886261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis.
    Tzouvelekis A; Yu G; Lino Cardenas CL; Herazo-Maya JD; Wang R; Woolard T; Zhang Y; Sakamoto K; Lee H; Yi JS; DeIuliis G; Xylourgidis N; Ahangari F; Lee PJ; Aidinis V; Herzog EL; Homer R; Bennett AM; Kaminski N
    Am J Respir Crit Care Med; 2017 Feb; 195(4):500-514. PubMed ID: 27736153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway.
    Yue B; Xiong D; Chen J; Yang X; Zhao J; Shao J; Wei D; Gao F; Huang M; Chen J
    Respir Res; 2024 Oct; 25(1):362. PubMed ID: 39369217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
    Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duvelisib attenuates bleomycin-induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway.
    Li X; Ma X; Miao Y; Zhang J; Xi B; Li W; Zhang Q; Chen L; Yang Y; Li H; Wei L; Zhou H; Yang C
    J Cell Mol Med; 2023 Feb; 27(3):422-434. PubMed ID: 36651446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis.
    Barnes JW; Duncan D; Helton S; Hutcheson S; Kurundkar D; Logsdon NJ; Locy M; Garth J; Denson R; Farver C; Vo HT; King G; Kentrup D; Faul C; Kulkarni T; De Andrade JA; Yu Z; Matalon S; Thannickal VJ; Krick S
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L141-L154. PubMed ID: 31042083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts.
    Tsoyi K; Esposito AJ; Sun B; Bowen RG; Xiong K; Poli F; Cardenas R; Chu SG; Liang X; Ryter SW; Beeton C; Doyle TJ; Robertson MJ; Celada LJ; Romero F; El-Chemaly SY; Perrella MA; Ho IC; Rosas IO
    Sci Rep; 2022 Feb; 12(1):2847. PubMed ID: 35181688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.
    Bamberg A; Redente EF; Groshong SD; Tuder RM; Cool CD; Keith RC; Edelman BL; Black BP; Cosgrove GP; Wynes MW; Curran-Everett D; De Langhe S; Ortiz LA; Thorburn A; Riches DWH
    Am J Respir Crit Care Med; 2018 Oct; 198(7):914-927. PubMed ID: 29727583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
    Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
    J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs.
    Marudamuthu AS; Shetty SK; Bhandary YP; Karandashova S; Thompson M; Sathish V; Florova G; Hogan TB; Pabelick CM; Prakash YS; Tsukasaki Y; Fu J; Ikebe M; Idell S; Shetty S
    J Biol Chem; 2015 Apr; 290(15):9428-41. PubMed ID: 25648892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL20Rb aggravates pulmonary fibrosis through enhancing bone marrow derived profibrotic macrophage activation.
    Zhu J; Jiang Q; Gao S; Xia Q; Zhang H; Liu B; Zhao R; Jiang H; Li X; Xu A; Zhou H; Xu Z; Yang C
    Pharmacol Res; 2024 May; 203():107178. PubMed ID: 38583686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of α
    Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM
    Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein tyrosine phosphatase-α amplifies transforming growth factor-β-dependent profibrotic signaling in lung fibroblasts.
    Aschner Y; Nelson M; Brenner M; Roybal H; Beke K; Meador C; Foster D; Correll KA; Reynolds PR; Anderson K; Redente EF; Matsuda J; Riches DWH; Groshong SD; Pozzi A; Sap J; Wang Q; Rajshankar D; McCulloch CAG; Zemans RL; Downey GP
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L294-L311. PubMed ID: 32491951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-laden macrophage-mediated paracrine profibrotic signaling induces lung fibroblast activation.
    Li Y; Du X; Hu Y; Wang D; Duan L; Zhang H; Zhang R; Xu Y; Zhou R; Zhang X; Zhang M; Liu J; Lv Z; Chen Y; Wang W; Sun Y; Cui Y
    Am J Physiol Cell Physiol; 2024 Oct; 327(4):C979-C993. PubMed ID: 39183565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogen-activated Protein Kinase-activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis.
    Liang J; Liu N; Liu X; Mena JM; Xie T; Geng Y; Huan C; Zhang Y; Taghavifar F; Huang G; Kurkciyan A; Barron V; Jiang D; Noble PW
    Am J Respir Cell Mol Biol; 2019 Jan; 60(1):41-48. PubMed ID: 30130411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.